Weight gain in bipolar disorder: pharmacological treatment as a contributing factor.
about
Neurocognitive functioning in overweight and obese patients with bipolar disorder: data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM)Inflammation: opportunities for treatment stratification among individuals diagnosed with mood disorders.Metabolic syndrome among psychiatric outpatients with mood and anxiety disorders.Effects of a multimodal lifestyle intervention on body mass index in patients with bipolar disorder: a randomized controlled trial.Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for PsychopharmacologyZiprasidone with adjunctive mood stabilizer in the maintenance treatment of bipolar I disorder: long-term changes in weight and metabolic profilesA 52-week, double-blind evaluation of the metabolic effects of aripiprazole and lithium in bipolar I disorder.Effect of Early Intervention with Omega-3 on Insulin Resistance in Patients Initiated on Olanzapine with either Sodium Valproate or Lithium: A randomized, Double-blind, Placebo-Controlled Trial.A psychoeducational intervention (SWEEP) for depressed women with diabetesComparison of body composition in persons with epilepsy on conventional & new antiepileptic drugs.Sequential behavioral treatment of smoking and weight control in bipolar disorder.Risk of myocardial infarction and stroke in bipolar disorder: a systematic review and exploratory meta-analysis.Genetic risk factors for type 2 diabetes with pharmacologic intervention in African-American patients with schizophrenia or schizoaffective disorder.Lithium: a key to the genetics of bipolar disorder.Managing weight in persons living with severe mental illness in community settings: a review of strategies used in community interventions.Lithium or Valproate Adjunctive Therapy to Second-generation Antipsychotics and Metabolic Variables in Patients With Schizophrenia or Schizoaffective Disorder.Weight gain associated with taking psychotropic medication: an integrative review.Metabolic syndrome and bipolar disorder: what should psychiatrists know?Olanzapine-induced weight gain in patients with bipolar I disorder: a meta-analysis.Obesity in bipolar disorder: an overview.Use of asenapine in clinical practice for the management of bipolar mania.Weight considerations in psychotropic drug prescribing and switching.Primary prevention of cardiovascular events in patients with major mental illness: a possible role for statins.Molecular and cellular regulation of hypothalamic melanocortin neurons controlling food intake and energy metabolism.Antiepileptic drugs influences on body weight in people with epilepsy.Treatment of clozapine-associated weight gain: a systematic review.Pharmacotherapy of acute mania: monotherapy or combination therapy with mood stabilizers and antipsychotics?Twenty-year progression of body mass index in a county-wide cohort of people with schizophrenia and bipolar disorder identified at their first episode of psychosis.Psychiatric and physical comorbidities and their impact on the course of bipolar disorder: A prospective, naturalistic 4-year follow-up study.Anti-inflammatory agents in the treatment of bipolar depression: a systematic review and meta-analysis.Is there a 'weight neutral' second-generation antipsychotic for bipolar disorder?Gender differences in mood stabilizer medications prescribed to Veterans with serious mental illness.Metformin for Lithium-induced Weight Gain: A Case Report.Prevalence and clinical impact of eating disorders in bipolar patients.Lower cognitive functioning as a predictor of weight gain in bipolar disorder: a 12-month study.Obesity in patients with major depression is related to bipolarity and mixed features: evidence from the BRIDGE-II-Mix study.Body mass index associates with white matter microstructure in bipolar depression.Aripiprazole plus divalproex for recently manic or mixed patients with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind maintenance trial.Asenapine in the management of impulsivity and aggressiveness in bipolar disorder and comorbid borderline personality disorder: an open-label uncontrolled study.
P2860
Q30897232-FD41C7D0-F130-49E9-BE50-CC1F0697992AQ33721019-B77E32DE-1C01-435B-8B22-40E073327477Q33836586-17C39822-FB82-49FD-B455-FFA5BE4C38E2Q34516264-480B1F3D-25F0-4C54-9BCA-60A4B1C9B48AQ34623350-AB98A16C-0CE0-462C-9D8B-EB113EF19273Q34676317-D9ABC1D3-CB5D-4F24-A4C3-1C518E53E3B2Q35577365-816E5622-0794-4616-9E03-DA3358754722Q35833294-4A3A6AEB-98D2-4243-9336-E46597ED1F35Q36197756-A4B0D72F-64A8-46BD-B1E9-4351EB37D457Q36929364-E5B69E12-A066-499A-BAC7-F86C0A8E2243Q36966140-E31FA9EF-16A2-4757-9D4B-4A6134AB6B07Q37031181-B7D1461B-E732-49D0-8A4E-4E96708B3A94Q37255608-4A956257-CC8B-4000-AA28-E184DE936ACEQ37365437-D9B984A3-070F-4EAA-AA06-41F8ED71A2A0Q37402610-174B9A05-51D8-426A-8A64-1190CBD2715DQ37623789-178749D7-5BFE-4E8A-9F7E-C71187B4F0DBQ37674020-1C9243C4-EE84-4607-A34B-0C079201FFF3Q37865068-78ABECC6-542D-4FF2-B56B-99463F6B2DB0Q37954425-5A1CE886-5889-4E82-875E-D33052301158Q37997775-9AA19546-A017-4FB9-AC6B-DFDB0E6A6093Q38035727-A29E55A2-81D7-4423-AFFB-665CE602A9D9Q38093728-3DE6E39A-1CC4-4E09-B7FC-E784AE557A89Q38151453-CB9D0BFE-EAF3-4EE2-9AB1-2AB9ECEB1804Q38151984-81880E4F-044F-477F-AE08-B353F2563EC1Q38204626-0B9A68C5-4271-45B9-80AE-136490920F5DQ38285318-E73E3249-08E1-456C-88C4-8C424E0C622BQ38334922-116F1227-6E2B-47E8-BE46-19D949316D16Q38364834-FBEE6FC4-E912-4D18-AE71-11B45A1EF03BQ38749110-A9DCA8E2-7DB1-4E08-A264-57E66D8EE07AQ38763807-E23FA330-397F-45F5-B5B3-589C6C04CB80Q38779572-57F3E0F8-23F3-414F-82B7-B989C1E06141Q39049252-A77EA20D-158D-4DAA-BCE6-94B01A3DB579Q40549171-357AF8F3-C5FF-4608-ADA9-636AB825BC7CQ41771822-E57E47AA-CC57-465A-A49D-347DEF1AF45AQ44632992-5DF0CD56-038A-4051-B406-F10236494518Q47249575-19A25538-B331-45CC-B82A-C93E449E9C09Q47704381-ACB7E684-FB4B-4890-A22C-DF0E8784BA67Q47913705-CA9A142E-487B-4355-A197-AF6CD26EFFCBQ48793990-00E63318-EBEB-496C-AD05-16E6E073428DQ49494206-6D8D2D02-5097-4CEF-9666-19CDE669D4BA
P2860
Weight gain in bipolar disorder: pharmacological treatment as a contributing factor.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Weight gain in bipolar disorder: pharmacological treatment as a contributing factor.
@en
Weight gain in bipolar disorder: pharmacological treatment as a contributing factor.
@nl
type
label
Weight gain in bipolar disorder: pharmacological treatment as a contributing factor.
@en
Weight gain in bipolar disorder: pharmacological treatment as a contributing factor.
@nl
prefLabel
Weight gain in bipolar disorder: pharmacological treatment as a contributing factor.
@en
Weight gain in bipolar disorder: pharmacological treatment as a contributing factor.
@nl
P2860
P50
P921
P1476
Weight gain in bipolar disorder: pharmacological treatment as a contributing factor
@en
P2093
P2860
P356
10.1111/J.1600-0447.2008.01204.X
P407
P50
P577
2008-05-22T00:00:00Z